The record
Written from the 1 report below. Nothing here is unsourced.
- Takeda Biopharmaceuticals India has received regulatory approval to market QDENGA, the first dengue vaccine approved in India, for use in the 4-60 years age group regardless of prior dengue exposure.
- The vaccine, which protects against all four dengue serotypes, will be imported from Germany and is expected to be available locally only in the first half of 2027, with pricing to be announced later.
- India carries nearly one-third of the global dengue burden, making this approval significant for the country's public health response.
- The approval is based on Takeda's global clinical trials involving over 28,000 participants, including a Phase III trial in Indian participants.
What to watch next
- Completion of remaining regulatory steps for imports that would allow local availability by the first half of 2027
- Announcement of pricing and availability details once local processes are complete
- Progress of indigenous dengue vaccine candidates from Panacea Biotec and Indian Immunologicals Ltd
Coverage1
1 report
English national1
All filed from India
Named India · Germany · Indian Immunologicals Ltd · Panacea Biotec · QDENGA · Sanofi · Biological E · Goh Choo Beng · Mahender Nayak · Peter Streibl · Takeda Biopharmaceuticals India · World Health Organization
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.